Franklin Resources Inc. increased its position in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 21.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 328,717 shares of the medical equipment provider’s stock after buying an additional 57,560 shares during the period. Franklin Resources Inc. owned 0.74% of ABIOMED worth $61,619,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. BlackRock Inc. boosted its holdings in ABIOMED by 2.1% during the fourth quarter. BlackRock Inc. now owns 3,525,206 shares of the medical equipment provider’s stock worth $660,658,000 after buying an additional 74,020 shares in the last quarter. Brown Capital Management LLC boosted its holdings in ABIOMED by 3.1% during the fourth quarter. Brown Capital Management LLC now owns 1,430,147 shares of the medical equipment provider’s stock worth $268,024,000 after buying an additional 43,076 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in ABIOMED by 102.0% during the third quarter. Janus Henderson Group PLC now owns 1,076,829 shares of the medical equipment provider’s stock worth $181,553,000 after buying an additional 543,793 shares in the last quarter. American Century Companies Inc. boosted its holdings in ABIOMED by 99.0% during the fourth quarter. American Century Companies Inc. now owns 963,517 shares of the medical equipment provider’s stock worth $180,573,000 after buying an additional 479,375 shares in the last quarter. Finally, Jackson Square Partners LLC boosted its holdings in ABIOMED by 4.2% during the fourth quarter. Jackson Square Partners LLC now owns 568,208 shares of the medical equipment provider’s stock worth $106,487,000 after buying an additional 23,101 shares in the last quarter. 88.42% of the stock is currently owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

A number of research firms have weighed in on ABMD. SunTrust Banks restated a “buy” rating and set a $370.00 price objective on shares of ABIOMED in a research report on Friday, February 16th. Jefferies Group restated a “buy” rating and set a $300.00 price objective on shares of ABIOMED in a research report on Thursday, February 1st. Guggenheim restated a “buy” rating and set a $280.00 price objective on shares of ABIOMED in a research report on Friday, February 2nd. Piper Jaffray Companies restated a “positive” rating and set a $300.00 price objective (up from $220.00) on shares of ABIOMED in a research report on Thursday, February 1st. Finally, Leerink Swann upped their price objective on shares of ABIOMED to $300.00 and gave the stock an “outperform” rating in a research report on Friday, February 2nd. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $288.86.

ABIOMED, Inc. (NASDAQ ABMD) opened at $293.05 on Friday. The firm has a market cap of $12,975.67, a price-to-earnings ratio of 152.63, a price-to-earnings-growth ratio of 4.06 and a beta of 0.25. ABIOMED, Inc. has a 12-month low of $117.36 and a 12-month high of $304.28.

ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.70 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.20. The company had revenue of $154.00 million during the quarter, compared to analysts’ expectations of $154.00 million. ABIOMED had a net margin of 16.58% and a return on equity of 15.54%. The firm’s revenue for the quarter was up 34.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.34 earnings per share. research analysts forecast that ABIOMED, Inc. will post 2.29 EPS for the current fiscal year.

In other news, VP Andrew J. Greenfield sold 20,000 shares of the stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $270.36, for a total value of $5,407,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.00% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.dailypolitical.com/2018/03/18/abiomed-inc-abmd-position-increased-by-franklin-resources-inc.html.

ABIOMED Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.